Pathogen Immunity, Signalling and Therapeutic Applications (PISTA)
The team focuses its research programme on the characterisation of infectious diseases and the development of new therapeutic strategies against these diseases and emerging infectious threats
The goal of the Pathogen Immunity Signalling and Therapeutic Applications (PISTA) group is to understand the underlying biology and features of human infection so as to develop novel therapeutic strategies against upcoming threats in a world that is becoming vulnerable to emerging pathogens that thrive due to globalization and climate change trends. As an emerging group studying emerging viruses, the team aims to lead rational design of broad antiviral treatments so as to fortify and strengthen preparedness against new viral threats, given that while infectious diseases can be contained by host defences, pathogens evolve to overcome immunity. In their endeavour to develop innovative antiviral strategies against microbial threats, the group collaborates with a range of clinical researchers, academic partners, and industries.
-
-
-
Immunization with V987H-stabilized Spike glycoprotein protects K18-hACE2 mice and golden Syrian hamsters upon SARS-CoV-2 infection.
Plitidepsin as an Immunomodulator against Respiratory Viral Infections.
Immunisation efficacy of a stabilised SARS-CoV-2 spike glycoprotein in two geriatric animal models.
A monoclonal antibody targeting a large surface of the receptor binding motif shows pan-neutralizing SARS-CoV-2 activity.
Pan-pox-specific T-cell responses in HIV-1-infected individuals after JYNNEOS vaccination.
-
-
News from the group
